Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

794 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Venadaparib Is a Novel and Selective PARP Inhibitor with Improved Physicochemical Properties, Efficacy, and Safety.
Lee M, Je IG, Kim JE, Yoo Y, Lim JH, Jang E, Lee Y, Song DK, Moon AN, Kim JA, Jeong J, Park JT, Lee JW, Yang JH, Hong CH, Park SY, Park YW, Baek NS, Lee S, Ha KS, Choi S, Lee WS. Lee M, et al. Among authors: park yw, park jt, park sy. Mol Cancer Ther. 2023 Mar 2;22(3):333-342. doi: 10.1158/1535-7163.MCT-22-0068. Mol Cancer Ther. 2023. PMID: 36808277 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 36805732
Preclinical development of a humanized neutralizing antibody targeting HGF.
Kim H, Hong SH, Kim JY, Kim IC, Park YW, Lee SJ, Song SW, Kim JJ, Park G, Kim TM, Kim YH, Park JB, Chung J, Kim IH. Kim H, et al. Among authors: park yw, park jb, park g. Exp Mol Med. 2017 Mar 24;49(3):e309. doi: 10.1038/emm.2017.21. Exp Mol Med. 2017. PMID: 28336956 Free PMC article.
First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients.
Kim ST, Hong JY, Park SH, Park JO, Park YW, Park N, Lee H, Hong SH, Lee SJ, Song SW, Kim K, Park YS, Lim HY, Kang WK, Nam DH, Lee JW, Park K, Kim KM, Lee J. Kim ST, et al. Among authors: park yw, park n, park ys, park sh, park jo, park k. Ther Adv Med Oncol. 2020 Jun 2;12:1758835920926796. doi: 10.1177/1758835920926796. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32536979 Free PMC article.
Phase I and pharmacokinetic study of the vascular-disrupting agent CKD-516 (NOV120401) in patients with refractory solid tumors.
Kim HK, Kang JW, Park YW, Kim JY, Kim M, Kim SJ, Kim SM, Ho Ryu K, Yoon S, Kim Y, Cho JY, Lee KS, Yun T, Kim K, Kwak MH, Kim TS, Chung J, Park JW. Kim HK, et al. Among authors: park yw, park jw. Pharmacol Res Perspect. 2020 Apr;8(2):e00568. doi: 10.1002/prp2.568. Pharmacol Res Perspect. 2020. PMID: 32162844 Free PMC article. Clinical Trial.
Selective Enhancement of Viewing Angle Characteristics and Light Extraction Efficiency of Blue Thermally Activated Delayed Fluorescence Organic Light-Emitting Diodes through an Easily Tailorable Si3N4 Nanofiber Structure.
Park JY, Lee S, Bi JC, Lee JS, Hwang YH, Kang B, Seok J, Park S, Lim D, Park YW, Ju BK. Park JY, et al. Among authors: park yw. ACS Appl Mater Interfaces. 2024 May 14. doi: 10.1021/acsami.4c00240. Online ahead of print. ACS Appl Mater Interfaces. 2024. PMID: 38743438
794 results